Phosphatidylinositol 3-kinase CB association with preoperative radiotherapy response in rectal adenocarcinoma

Table 3 Multivariate analysis for important clinicopathological and phosphatidylinositol 3-kinase CB expression

Parameter			DSS		LRFS		MeFS
		No. c	No. e	P value	No. e	P value	No. e	P value
Sex	Male	120	43	0.554	109	0.476	90	0.109
	Female	88	27		86		64
Age in years	< 65	140	49	0.769	130	0.502	99	0.173
	≥ 65	68	21		65		55
TH in cm	< 5	74	28	0.053	66	0.072	56	0.004
	≥ 5	134	42		129		98
PreTNM	II	29	7	0.544	27	0.959	23	0.437
	III	161	581 (5)		1481 (20)		1151 (16)
BMI	0	11	5	0.008	11	0.628	6	0.906
	1	105	29		96		84
	2	76	31		72		52
	3	16	5		16		13
LVI	Negative	21	11	0.506	19	0.647	12	0.115
	Positive	187	59		176		142
Diff.	ypCR	11	11 (1)	0.189	111 (1)	0.974	10	0.951
	G1-2	146	48		139		108
	G3-4	50	20		44		36
ypT	T0	8	1	0.359	8	0.374	8	0.544
	T1	11	4		11		8
	T2	55	8		54		48
	T3	134	57		122		90
ypN	0	122	25	0.043	116	0.000	103	0.005
	1	55	24		52		34
	2	31	21		27		17
TRG	1 (G1-2)	32	5	0.020	31	0.018	28	0.021
	2 (G3)	79	25		77		56
	3 (G4-5)	97	40		87		70
PIK3CB	Low exp	67	19	0.124	62	0.011	51	0.010
	High exp	141	51		133		103

¹Lack of number of patients. DSS: Disease-specific survival; LRFS: Local recurrence-free survival; MeFS: Metastasis-free survival; PIK3: Phosphatidylinositol 3-kinase; TH: Tumor height; BMI: Body mass index; LVI: Lymph vessel invasion; TRG: Tumor regression grade.